During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.

Additional Metadata
Persistent URL dx.doi.org/10.1038/s41467-018-05727-y, hdl.handle.net/1765/110402
Journal Nature Communications
Citation
Koller, M. (Marjory), Qiu, S.-Q. (Si-Qi), Linssen, M.D. (Matthijs D.), Jansen, L. (Liesbeth), Kelder, W. (Wendy), de Vries, J.A.G.E, … van Dam, G.M. (2018). Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nature Communications, 9(1). doi:10.1038/s41467-018-05727-y